mResell levererade 131 % intäktstillväxt i Q4’25 trots en temporär regulatorisk påverkan.
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust i det fjärde kva...
Hanza redovisade ett starkt bokslut för 2025 med rekordhög marginal.
Redeye returns with an update following Guldbrev's mixed Q4 report that posted stronger growth than ...
Redeye comments on MindArk’s Q4 results, which came in somewhat softer than expected.
Redeye provides its initial take on Heliospectra’s Q4 results, which showed softer-than-expected fig...
Redeye provides an initial take following Paxman’s Q4 2025 report.
Physitracks Q4 results aligned with its preliminary figures, highlighted by continued margin expansi...
Redeye views Xplora's Q4 2025 results positively despite a miss against its own forecasts, as the pr...
With key trials successfully initiated and the balance sheet strengthened in 2025, Curasight is set ...
* Q4 sales and EBITDA 7% and EBITDA 23% above driven by Senior * Strong growth in senior device reve...
IDL saw a comeback in TUBEX in Q3, and total sales came in SEK1m above our forecast, with OPEX relat...
Xplora's gross profit came in stronger than expected at NOK 312m, 7% higher than consensus, driven b...
Redeye comments on Sivers’ Q4 report, which showed solid FX-neutral growth and strong Photonics hard...
Tallinna Sadam's revenue growth was 1% y/y and close to consensus (LSEG Data & Analytics) expectatio...
Incap's Q4 net sales missed market consensus (LSEG Data & Analytics), but profitability was better t...
Redeye provides a research update following the Q4 report published by OncoZenge earlier today.
Fluoguide continued its track record of good cost control in Q4, and reported remaining cash and ST ...
Operationella förutsättningar för en återhämtning är lagda, men marknadsläget försvårar prognostiser...
Profitability (adj. EBIT margin) was better than market consensus (LSEG) expected in Q4.
